

**Fax Referrals To:** (855) 891-2191 **Have a Question?** (855) 478-1528

## NUCALA® (MEPOLIZUMAB) ORDER FORM

(\* - Required Fields)

## \_\_\_\_ STAT REQUEST

(\*REASON MUST BE PROVIDED BELOW)

New Referral Order Renewa Benefits Verification Only	Medication/Order Change	Locations:
PATIENT INFOI		Tulsa
NAME*:	DOB*: SEX: M	<u>F</u>
ADDRESS: WEIGHT: LBS KG HEIGHT:	PHONE:	
WEIGHT: LBS KG HEIGHT: ALLERGIES:	EMAIL:	
ALLENGIES.		
PHYSICIAN INFORMATION		
PHYSICIAN NAME*:	PRACTICE NAME:	
ADDRESS:	OFFICE CONTACT*:	
PHONE: FAX:	EMAIL (FOR UPDATES):	
NUCALA ORDER*: (SELECT ONE OF THE FOLLOWING)	ICD-10*:	
Dosing: 100 mg administered subcutaneously once every 4 weeks		
OR		
Dosing: 300 mg as 3 separate 100-mg injections administered subcutaneously once every 4 weeks		
Physician Signature* D	ate*(Order is Valid for One Year)	_
REQUIRED DIAGNOSIS:	REQUIRED DOCUMENTATION CHECKLIS	5T:
Severe Asthma	Patient Demographics	
Eosinophilic Asthma	Insurance Card/Information	
Eosinophilic Granulomatosis with Polyangiitis	Clinical/Progress Notes supporting	DX
Other	Current Medication List and H&P	
*STAT REASON:	Absolute Eosinophil Count (> 300 ir prior 12mos or > 150 in prior 6 wee	
(STAT request will be assessed per MPP policy and protocol)	Anti-neutrophil cytoplasmic antiboo (ANCA) positive within 6 months (Required for Eosinophilic Granulomatosis with Polyang	
	Last Infusion/Injection Date:	
STANDING LAB ORDERS: CMP CBC		
Labs to be drawn by Infusion Center Frequency	,	
NOTES/ADDITIONAL COMMENTS:		
		REVISION DATE- 05/2020